EY Names Elizabeth Iorns of Science Exchange As Entrepreneur Of The Year® 2018 Award Finalist in Northern California

May 17, 2018 | Posted by Team in News |

PALO ALTO, CA, May 16, 2018 – EY announced that Elizabeth Iorns, Ph.D., CEO and co-founder of Science Exchange, is a finalist for the Entrepreneur Of The Year® 2018 Award in the Northern California region. Entrepreneur Of The Year® is the world’s most prestigious business awards program for entrepreneurs who are excelling in areas such as innovation, financial performance and personal commitment to their businesses and communities. Iorns was selected as a finalist by a panel of independent judges. Award winners will be announced at a special gala event on June 8 at the Fairmont San Francisco.

“I am truly honored to be included as an Entrepreneur Of The Year®finalist among so many other accomplished business luminaries in Northern California,” noted Elizabeth Iorns. “I share this honor with every Science Exchange team member who strives daily to improve the quality and efficiency of scientific research.”

Iorns is a resolute leader dedicated to speeding up scientific research and making it more collaborative. Under her leadership, Science Exchange, the leading marketplace for outsourced R&D, has been enabling scientific breakthroughs by connecting researchers to the best R&D providers.

Iorns has received many other accolades that validate her commitment and groundbreaking work in the industry, including the Gold Stevie® Award for Female Entrepreneur of the Year, Nature’s “Ten People that Mattered,” WIRED’s “50 Women Who Are Changing The World” and the Glamstarter Award from Glamour Magazine.

Now in its 32nd year, the Entrepreneur Of The Year® program has expanded to recognize business leaders in more than 145 cities and more than 60 countries throughout the world.

Regional award winners are eligible for consideration for the Entrepreneur Of The Year National competition. Award winners in several national categories, as well as the Entrepreneur Of The Year National Overall Award winner, will be announced at the Entrepreneur Of The Year National Awards gala in Palm Springs, California, on November 17, 2018. The awards are the culminating event of the Strategic Growth Forum®, the nation’s most prestigious gathering of high-growth, market-leading companies.

 

About Entrepreneur Of The Year®

Entrepreneur Of The Year®, founded by EY, is the world’s most prestigious business awards program for entrepreneurs, chosen from an independent panel of judges including entrepreneurs and prominent leaders from business, finance, and the local community. The program makes a difference through the way it encourages entrepreneurial activity among those with potential and recognizes the contribution of people who inspire others with their vision, leadership and achievement. As the first and only truly global awards program of its kind, Entrepreneur Of The Year celebrates those who are building and leading successful, growing and dynamic businesses, recognizing them through regional, national and global awards programs in more than 145 cities and more than 60 countries. ey.com/eoy

Take 5 – The Transcending Power of Innovation

May 11, 2018 | Posted by Team in Innovation Highlight |

by Gursatya “Guru” Singh, Director of Scientific Content, Science Exchange

Innovation is the spice of life; it brings out the complex flavors of our ideas and elevates them to new heights. Scientific research becomes stagnant without it, as does just about every other profession. To put it plainly, innovative breakthroughs have the potential to challenge the way we think and live. Within the past few years, we have witnessed significant paradigm shifts within life science research thanks to breakthroughs from several sources such as Silicon Valley tech startups, biotech companies, CROs, academic labs, and government institutes.

To illustrate, some providers in our network now offer virtual reality services for highly-advanced 3D molecular visualization, while others provide blockchain technology to help you protect your IP (intellectual property)  and facilitate secure data storage and transfer. These providers and many more can be found on Science Exchange — offering services ranging from artificial intelligence platforms that help scientists make better drug efficacy predictions early in the research cycle, to highly inventive 3D organoid models that recapitulate human pathology in vitro. As such, we have witnessed many technologies of the future become the reality of today. Science Exchange has been and will always be ready to give you access to innovative technologies before they become mainstream.

Sit back and Take 5! If something grabs your interest, click on the provided link to learn more about each service.

paragon-assay

Paragon Assay – An RNA-Based Immune Profiling
This assay reports on the most impactful immunomodulatory molecules demonstrated to have implications in drug discovery, biomarker development, and immunotherapy efficacy monitoring.

Clinical archives and samples, such as FFPE, FNAs, CNBs, and LCM solid tumors, have previously been difficult to characterize. Paragon accommodates these valuable and degraded materials with very low inputs and provides extensive immune characterization beyond current technologies—including differentiating cells such as M1 and M2 macrophages and Tregs—with high confidence. LEARN MORE

 

Organotypic 3D Lung Model
This model mimics the architecture and functions of the human airway epithelium in vitro and can be used for the assessment of goblet cell hyperplasia, mucus secretion, squamous cell development, and changes in gene expression.

The organotypic 3D lung model provides actionable data on the effects of test compounds in a rapid and reproducible manner. It has the potential to reveal differential effects of novel therapeutics on cells from non-diseased and diseased donors. LEARN MORE

 

BSEPcyte® and MDR3cyte® Assay Services
These novel Bile Salt Export Protein (BSEP)/Multi-Drug-Resistant Protein 3 (MDR3) inhibition assay services are useful in assessing the potential of candidate drugs in treating drug-induced liver injury (DILI).

BSEPcyte® and MDR3cyte® employ primary hepatocyte suspensions and have a significant competitive advantage over assay systems that employ membrane vesicles in being physiologically relevant and capable of cross-species comparison and in situ metabolism investigations. LEARN MORE

 

theraTRACE® Phenotypic Screening PlatformtheraTRACE® Phenotypic Screening Platform
This platform allows for known drug-like compounds to be comprehensively screened using a battery of in vivo assays (> 40 animal models) spanning multiple therapeutic areas.

The theraTRACE® system is able to provide a complete pharmacological fingerprint/profile of a compound in 10 weeks. The system demonstrates particular utility in facilitating the crucial “go/no-go” development decisions routinely faced by pharmaceutical and biopharmaceutical companies. LEARN MORE

 

Simple WesternSimple Western™ Assays
These assays can be used for protein sizing and quantitative immunodetection as an alternative to traditional Western blot analysis.

Simple Western™ assays are performed on Simon™, an instrument that integrates and automates all manual operations associated with Western blotting. LEARN MORE

 

 

Request quotes for these innovative services today!

request quotes button

Science Exchange Named Finalist for 2018 Bio-IT World Best Practices Awards

May 8, 2018 | Posted by Team in News |

2018 Bio-IT World Best Practices Award Finalist

We’re finalists! Our entry, Procurement as Innovative Driver,” describing our collaboration with GSK Consumer Health, could win a 2018 Bio-IT World Best Practices Award next week. Read the announcement and full list of nominees at http://www.bio-itworld.com/2018/04/20/bio-it-world-announces-finalists-for-2018-best-practices-awards.aspx.

 

On-Demand Webinar: Complex, 3D Screening for Cancer Immunotherapy

May 7, 2018 | Posted by Team in Webinar |

CARE Research, LLC Preclinical Services

Screening for potential anti-cancer immunotherapies benefits from 3D platforms to detect complex, multi-cell and multi-step effects on the immune system.

Watch this on-demand webinar to learn:

  • Differences between 2D and 3D drug screening models
  • How 3D cultures can mimic cancer cell-immune cell interactions
  • How to maximize reproducibility in a 3D drug screening assay

View Webinar button

Who Should Watch:

  • Assay development researchers
  • Cancer immunotherapy researchers
  • Cell biologists

About Our Speakers:

Lisa Stehno-Bittel, Ph.D. co-founded Likarda in 2012. In 17 months, Likarda was revenue positive and was chosen as one of the top 50 Most Promising Start-Ups in the World. With over 25 years of experience studying cell biology and diabetes, she has over 65 publications and many awards. Currently, Lisa and her team at Likarda are developing a cell-based solution for dogs with diabetes, removing the need for daily insulin injections.

Lindsey Ott, Ph.D. is the Director of Product Innovation at Likarda LLC. In her role at Likarda, Lindsey expands Likarda’s patented 3D cell cluster technology into other preclinical drug discovery applications like oncology, immunotherapies, and ADME-Tox.

About Science Exchange

We are transforming scientific collaboration by creating a marketplace where scientists can order experiments from the world's top labs.

Check the Science Exchange blog for updates, opinions, guest posts and the latest happenings at Science Exchange HQ!

Visit Science Exchange →

Subscribe to the blog
Never miss a post! Science Exchange blog posts delivered right to your inbox.
Thank you for joining the SciEx revolution!
Powered By WPFruits.com